Detailed Pharmacognostical and Pharmaceutical Evaluation of Combine Formulation of Triphala Yavakuta (1:2:4)

Triphala is an important Ayurvedic formulation containing, Haritaki (Terminalia chebula Retz),Vibhitaki (Terminalia bellarica Roxb),Amalaki (Emblica officinalis L.) as a ingredients. All the constituents are available and prepared according to the reference present in Yoga Ratnakara Madhyama Khanda. Triphala (Haritaki, Vibhitaki and Amalaki) classified as an important medicine of the Rasayana and Cakshusya group which is mainly indicated in Prameha, Sthoulya and Kustha and also it is believed to promote health, immunity and longevity. Though they are individually very potent drug and have their own specific mode of action on different disease conditions. Triphala the sense of its Rasa, Vipaka and to some extent its Prabhava is similar to its three contents but its Virya, Doshagnata and Guna are not exactly similar to the composing three drugs. This is due to Samyoga Samskara by which the clinical efficacy of particular drug changes several methods are adopted to prepare Triphala some uses equal proportions (1:1:1) some in different proportions (1:2:4). Till date there is only one scientific work has been carried out and less publication of 1:2:4 combination forms of Triphala. In the present study the Yavakuta formulation of Triphala was subjected to Pharmacognostical (microscopic), HPTLC, and pharmaceutical (evaluation of various physiochemical parameters) evaluation in order to prepare a preliminary profile of the formulation. The sample was subjected for various phytochemical parameters like water soluble extractive (55.8%w/w), alcohol soluble extractive (42.2% w/w), ash value (0.89% w/w), loss on drying (11.39% w/w), and the pH (5.0), HPTLC. The HPTLC, solvent system was Toluene:ethyl acetate (9:1), showed the presence of 5 spots at 254 nm and 2 spots at 366 nm. Thus the physiochemical and microscopic characters achieved may provide guidelines for standardization of formulation, Triphala Yavakuta combine formulation (1:2:4).